Key result
Personalized antiplatelet therapy guided by algorithms and platelet testing may reduce major cardiovascular events and stent thrombosis.
Why the study?
Does personalized tailoring of antiplatelet therapy guided by platelet function testing reduce MACE and stent thrombosis in patients following PCI?
Does personalized tailoring of antiplatelet therapy guided by platelet function testing reduce MACE and stent thrombosis in patients following PCI?
Personalized antiplatelet therapy using platelet function testing and newer agents like prasugrel and ticagrelor may help overcome clopidogrel hyporesponsiveness and reduce post-PCI ischemic events.
Answers are grounded in this paper and cite their sources.
May support individualized post-PCI antiplatelet strategies; leaves open confirmation in randomized trials before practice change.
Current guidelines recommend dual antiplatelet therapy (DAPT), which includes aspirin and a platelet P2Y(12) adenosine diphosphate (ADP) receptor antagonist, for treatment of patients with acute coronary syndrome and following percutaneous coronary intervention (PCI). Although DAPT significantly reduces stent thrombosis and major adverse cardiovascular events (MACE), there is considerable interindividual variability in the degree of platelet inhibition achieved with the most widely used ADP receptor antagonist, clopidogrel, and high on-treatment platelet activity in the setting of clopidogrel therapy (hyporesponsiveness) is associated with increased adverse cardiovascular events following PCI. Personalized tailoring of antiplatelet therapy guided by patient management algorithms and/or platelet function testing has the potential to reduce MACE and stent thrombosis. This article outlines specific algorithms for using potent new antiplatelet agents, such as prasugrel and ticagrelor, and platelet function "test and treat-to-target" strategies to reduce adverse cardiovascular events following PCI.
No takes yet. Share an insight, caveat, or question.
Lassar et al. (2011) conducted a review in Acute coronary syndrome and percutaneous coronary intervention. Platelet function testing and tailored antiplatelet therapy was evaluated. Personalized tailoring of antiplatelet therapy guided by patient management algorithms and platelet function testing has the potential to reduce major adverse cardiac events and stent thrombosis.
Synapse has enriched 10 related papers. Consider them for comparative context: